There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient's anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient's immune system are themselves targeted by the patient's immune system, inducing neutralizing and suppressive responses.
But now, a team of researchers, led by Michael Morse, at Duke University Medical Center, Durham, has developed a way to overcome these neutralizing and suppressive responses by using an alphavirus packaged in virus-like replicon particles.
Repeated administration of such particles carrying the tumor protein CEA to patients with metastatic cancer expressing CEA induced clinically relevant immune responses targeted to CEA. As the presence of such immune responses was associated with longer overall patient survival, the authors hope their approach might be of therapeutic use in many cancer settings.
The research appears in the Journal of Clinical Investigation.
The above post is reprinted from materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.
- Michael A. Morse, Amy C. Hobeika, Takuya Osada, Peter Berglund, Bolyn Hubby, Sarah Negri, Donna Niedzwiecki, Gayathri R. Devi, Bruce K. Burnett, Timothy M. Clay, Jonathan Smith and H. Kim Lyerly. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI42672
Cite This Page:
Journal of Clinical Investigation. "Boosting the efficacy of anticancer vaccines." ScienceDaily. ScienceDaily, 2 August 2010. <www.sciencedaily.com/releases/2010/08/100802125817.htm>.
Journal of Clinical Investigation. (2010, August 2). Boosting the efficacy of anticancer vaccines. ScienceDaily. Retrieved July 31, 2016 from www.sciencedaily.com/releases/2010/08/100802125817.htm
Journal of Clinical Investigation. "Boosting the efficacy of anticancer vaccines." ScienceDaily. www.sciencedaily.com/releases/2010/08/100802125817.htm (accessed July 31, 2016).